BODI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BODI is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The technical setup is mixed to positive in the very short term, but the stock is already extended and the probability-based trend outlook is negative over the next day, week, and month. Analyst sentiment is improving, but the business still faces legacy runoff and uncertain product velocity, and there is no recent news or insider/congress buying catalyst. Given the investor profile and the lack of a strong edge, the better call is to wait rather than buy now.
The chart is constructive but stretched. MACD histogram is positive and expanding, and the moving averages are bullish with SMA_5 > SMA_20 > SMA_200, which supports an uptrend. However, RSI_6 is 77.408, indicating the stock is overbought in practical terms despite being labeled neutral in the data. Price at 10.68 is just above pivot 9.539 and near first resistance at 10.616, with the next resistance at 11.282. The stock also closed slightly below the prior close, and the pattern-based forecast suggests downside of -2.36% next day, -4.73% next week, and -7.74% next month. Overall: short-term momentum is positive, but the current entry is not attractive for a beginner long-term buyer.
["Canaccord raised its target to $19 and maintained a Buy rating, citing improving profitability after the move away from MLM and expected sales inflection.", "Noble Capital raised its target to $22 and kept an Outperform rating after Q1 results exceeded expectations.", "Roth Capital raised its target to $13 from $10 after Q1 results, showing improving analyst expectations overall.", "Bullish technical trend: MACD is positive and expanding, with SMA_5 > SMA_20 > SMA_200.", "Potential retail launches are planned, which could support future revenue growth if execution improves."]
["Sequential growth in legacy businesses remains negative.", "Product velocity remains uncertain, which weakens confidence in near-term business momentum.", "No news in the recent week, so there is no fresh catalyst from the market or company.", "Hedge funds are neutral with no significant trends over the last quarter.", "Insiders are neutral with no significant trends over the last month.", "No recent congress trading data available.", "Pattern-based stock trend analysis indicates a high chance of short-term declines."]
No usable financial snapshot was provided because the financial data returned an error. The only available earnings-related detail is that Q1 results exceeded expectations, and analysts cited improving profitability. That said, the company still appears to be in a transition phase, with legacy business runoff continuing and growth not yet clearly established. Latest quarter season: Q1.
Wall Street sentiment has improved, but the overall view is still mixed. Roth Capital raised its target to $13 and stayed Neutral, pointing to negative sequential legacy growth and uncertain retail launch productivity. Noble Capital raised its target to $22 and kept an Outperform rating after Q1 beat expectations despite runoff. Canaccord lifted its target to $19 and maintained Buy, expecting better profitability and a possible sales inflection after the MLM model shift. Pros: rising price targets, better profitability outlook, and a post-Q1 confidence boost. Cons: legacy business decline, execution uncertainty, and only one Neutral rating among the updates, so conviction is positive but not yet strong enough for a beginner long-term purchase today.
